• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
SARS-CoV-2: the "Uncensored" Truth about Its Origin and Adipose-Derived Mesenchymal Stem Cells as New Potential Immune-Modulatory Weapon.严重急性呼吸综合征冠状病毒2:关于其起源及脂肪来源间充质干细胞作为新型潜在免疫调节武器的“未经审查”的真相
Aging Dis. 2021 Apr 1;12(2):330-344. doi: 10.14336/AD.2021.0121. eCollection 2021 Apr.
2
Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem Cells (AD-MSCs), Drugs, and Vaccines in Inhibiting COVID-19 Disease.间充质干细胞(MSCs)、脂肪来源间充质干细胞(AD-MSCs)、药物及疫苗在抑制新型冠状病毒肺炎方面的研究进展
Aging Dis. 2020 Oct 1;11(5):1191-1201. doi: 10.14336/AD.2020.0711. eCollection 2020 Oct.
3
Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Severe COVID-19 Patients.经血来源的间充质干细胞治疗重症 COVID-19 患者。
Curr Stem Cell Res Ther. 2024;19(5):644-652. doi: 10.2174/1574888X18666230417085117.
4
Virology of SARS-CoV-2 and management of nCOVID-19 utilizing immunomodulation properties of human mesenchymal stem cells-a literature review.利用人间充质干细胞免疫调节特性对严重急性呼吸综合征冠状病毒2型进行病毒学研究及新型冠状病毒肺炎的管理——文献综述
Stem Cell Investig. 2021 Nov 10;8:23. doi: 10.21037/sci-2020-040. eCollection 2021.
5
Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.扩充脐带间充质干细胞(UC-MSCs)作为治疗危重症 COVID-19 患者的一种治疗策略:同情用药的理由。
Pain Physician. 2020 Mar;23(2):E71-E83.
6
Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?干细胞与 COVID-19:人类羊膜细胞是否为对抗 SARS-CoV-2 病毒治疗的新希望?
Stem Cell Res Ther. 2021 Mar 1;12(1):155. doi: 10.1186/s13287-021-02216-w.
7
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection.人骨髓间充质干细胞不表达 ACE2 和 TMPRSS2,并且不易感染 SARS-CoV-2。
Stem Cells Transl Med. 2021 Apr;10(4):636-642. doi: 10.1002/sctm.20-0385. Epub 2021 Jan 26.
8
Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.脂肪干细胞(ASCs)和基质血管成分(SVF)作为对抗冠状病毒病(COVID-19)的潜在疗法
Aging Dis. 2020 May 9;11(3):465-469. doi: 10.14336/AD.2020.0422. eCollection 2020 May.
9
Mesenchymal stem cells and their derived exosomes to combat Covid-19.间充质干细胞及其衍生的外泌体对抗新冠病毒。
Rev Med Virol. 2022 Mar;32(2):e2281. doi: 10.1002/rmv.2281. Epub 2021 Aug 7.
10
Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.间充质干细胞及其分泌组在治疗新型冠状病毒肺炎中的效力
Regen Eng Transl Med. 2022;8(1):43-54. doi: 10.1007/s40883-021-00202-5. Epub 2021 Mar 10.

引用本文的文献

1
Proteins from Stressed Mesenchymal Stem Cells Can Repair Hair Follicles and Promote Hair Regeneration.应激间充质干细胞产生的蛋白质可修复毛囊并促进头发生长。
ACS Pharmacol Transl Sci. 2025 May 24;8(6):1768-1777. doi: 10.1021/acsptsci.5c00184. eCollection 2025 Jun 13.
2
The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy.间充质干细胞的异质性:细胞治疗中需要解决的一个重要问题。
Stem Cell Res Ther. 2023 Dec 20;14(1):381. doi: 10.1186/s13287-023-03587-y.
3
Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis.新型冠状病毒肺炎患者间充质干细胞治疗的安全性和有效性:系统评价和荟萃分析。
Immun Inflamm Dis. 2023 Sep;11(9):e1000. doi: 10.1002/iid3.1000.
4
Complications of COVID-19 on the Central Nervous System: Mechanisms and Potential Treatment for Easing Long COVID.新型冠状病毒肺炎对中枢神经系统的并发症:缓解新冠后症状的机制及潜在治疗方法
Aging Dis. 2023 Oct 1;14(5):1492-1510. doi: 10.14336/AD.2023.0312.
5
An Update on Adipose-Derived Stem Cells for Regenerative Medicine: Where Challenge Meets Opportunity.脂肪来源干细胞在再生医学中的最新进展:挑战与机遇并存。
Adv Sci (Weinh). 2023 Jul;10(20):e2207334. doi: 10.1002/advs.202207334. Epub 2023 May 10.
6
Methods and Limitations of Augmenting Mesenchymal Stem Cells for Therapeutic Applications.方法和局限性:增强间充质干细胞在治疗应用中的作用。
Adv Wound Care (New Rochelle). 2023 Aug;12(8):467-481. doi: 10.1089/wound.2022.0107. Epub 2022 Dec 8.
7
Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies.与 COVID-19 相关的脱发和休止期脱发:脂肪来源间充质干细胞和富血小板血浆作为再生策略的潜在意义。
Int J Mol Sci. 2022 Aug 14;23(16):9116. doi: 10.3390/ijms23169116.
8
Knockout of integrin β1 in induced pluripotent stem cells accelerates skin-wound healing by promoting cell migration in extracellular matrix.诱导多能干细胞中整合素 β1 的敲除通过促进细胞在细胞外基质中的迁移加速皮肤伤口愈合。
Stem Cell Res Ther. 2022 Jul 30;13(1):389. doi: 10.1186/s13287-022-03085-7.
9
Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis.间充质干细胞治疗新型冠状病毒肺炎重症/危重症患者的安全性和有效性:一项系统评价与Meta分析
EClinicalMedicine. 2022 Jul 9;51:101545. doi: 10.1016/j.eclinm.2022.101545. eCollection 2022 Sep.
10
Bone marrow mesenchymal stem cells facilitate diabetic wound healing through the restoration of epidermal cell autophagy via the HIF-1α/TGF-β1/SMAD pathway.骨髓间充质干细胞通过 HIF-1α/TGF-β1/SMAD 通路恢复表皮细胞自噬促进糖尿病创面愈合。
Stem Cell Res Ther. 2022 Jul 15;13(1):314. doi: 10.1186/s13287-022-02996-9.

本文引用的文献

1
SARS-CoV-2 spillover events.严重急性呼吸综合征冠状病毒2溢出事件。
Science. 2021 Jan 8;371(6525):120-122. doi: 10.1126/science.abf6097.
2
Research progress on Mesenchymal Stem Cells (MSCs), Adipose-Derived Mesenchymal Stem Cells (AD-MSCs), Drugs, and Vaccines in Inhibiting COVID-19 Disease.间充质干细胞(MSCs)、脂肪来源间充质干细胞(AD-MSCs)、药物及疫苗在抑制新型冠状病毒肺炎方面的研究进展
Aging Dis. 2020 Oct 1;11(5):1191-1201. doi: 10.14336/AD.2020.0711. eCollection 2020 Oct.
3
Exosome therapeutics for lung regenerative medicine.用于肺再生医学的外泌体疗法
J Extracell Vesicles. 2020 Jun 29;9(1):1785161. doi: 10.1080/20013078.2020.1785161.
4
Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia.间充质干细胞衍生的外泌体在 SARS-CoV-2 肺炎中的潜在治疗应用。
Stem Cell Res Ther. 2020 Aug 14;11(1):356. doi: 10.1186/s13287-020-01866-6.
5
Systematic Review: Allogenic Use of Stromal Vascular Fraction (SVF) and Decellularized Extracellular Matrices (ECM) as Advanced Therapy Medicinal Products (ATMP) in Tissue Regeneration.系统评价:基质血管成分(SVF)和去细胞细胞外基质(ECM)作为组织再生的高级治疗药物(ATMP)的同种异体应用。
Int J Mol Sci. 2020 Jul 15;21(14):4982. doi: 10.3390/ijms21144982.
6
Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.脂肪干细胞(ASCs)和基质血管成分(SVF)作为对抗冠状病毒病(COVID-19)的潜在疗法
Aging Dis. 2020 May 9;11(3):465-469. doi: 10.14336/AD.2020.0422. eCollection 2020 May.
7
Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.骨髓间充质干细胞来源的外泌体治疗重症 COVID-19。
Stem Cells Dev. 2020 Jun 15;29(12):747-754. doi: 10.1089/scd.2020.0080. Epub 2020 May 12.
8
Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia.脂肪来源的间充质干细胞(ASCs)作为一种新型的再生即时疗法,用于对抗冠状病毒(COVID-19)引起的肺炎。
Expert Opin Biol Ther. 2020 Jul;20(7):711-716. doi: 10.1080/14712598.2020.1761322. Epub 2020 Apr 29.
9
Exosome-based delivery of super-repressor IκBα relieves sepsis-associated organ damage and mortality.基于外泌体的超抑制型 IκBα 递送缓解脓毒症相关的器官损伤和死亡率。
Sci Adv. 2020 Apr 8;6(15):eaaz6980. doi: 10.1126/sciadv.aaz6980. eCollection 2020 Apr.
10
Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia.间充质干细胞输注显示出对抗冠状病毒(COVID-19)诱发肺炎的潜力。
Aging Dis. 2020 Mar 9;11(2):462-464. doi: 10.14336/AD.2020.0301. eCollection 2020 Apr.

严重急性呼吸综合征冠状病毒2:关于其起源及脂肪来源间充质干细胞作为新型潜在免疫调节武器的“未经审查”的真相

SARS-CoV-2: the "Uncensored" Truth about Its Origin and Adipose-Derived Mesenchymal Stem Cells as New Potential Immune-Modulatory Weapon.

作者信息

Gentile Pietro

机构信息

1Department of Surgical Science, Plastic and Reconstructive Surgery, "Tor Vergata" University, Rome, 00133, Italy.

2Founder and Scientific Director of Academy of International Regenerative Medicine & Surgery Societies (AIRMESS), 1201 Geneva, Switzerland.

出版信息

Aging Dis. 2021 Apr 1;12(2):330-344. doi: 10.14336/AD.2021.0121. eCollection 2021 Apr.

DOI:10.14336/AD.2021.0121
PMID:33815867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7990360/
Abstract

In this second return of the pandemic, January 2021, it appears to be clear that a Nano-sized organism, the SARS-CoV-2, has rendered the human race helpless, made the global health status decline, and drowned the world economy. However, it does not appear clear the real origin of the SARS-CoV-2 and the aim of this work is to report and discuss, maybe for the first time since the pandemic began, the scientific data published in this specific field, analyzing the potentially available weapons against the SARS-CoV-2. About this last point, a ray of hope comes from the potential of Mesenchymal Stem Cells (MSCs) that has already been established in Coronavirus Disease 2019 (COVID-19), and in particular from the Adipose-Derived Mesenchymal Stem Cells (AD-MSCs). However, cell-based therapy has its own limits, especially represented by the know-how in this field and by the rules of applications. It was suggested a biological therapy using AD-MSCs as a weapon against COVID-19, as they can be a game-changer owing to their immuno-modulatory nature, which combats the cytokine storm characterizing this disease, and their practical efficiency, which will realistically aid large access to therapy worldwide.

摘要

在2021年1月疫情的这第二轮反扑中,似乎很明显,一种纳米级别的生物体——严重急性呼吸综合征冠状病毒2(SARS-CoV-2),已使人类束手无策,导致全球健康状况下降,并拖累了世界经济。然而,SARS-CoV-2的真正起源似乎并不明确,而这项工作的目的是报告并讨论,也许是自疫情开始以来首次,该特定领域已发表的科学数据,分析针对SARS-CoV-2的潜在可用武器。关于最后这一点,一线希望来自间充质干细胞(MSCs)的潜力,这种潜力在2019冠状病毒病(COVID-19)中已经得到证实,尤其是来自脂肪来源的间充质干细胞(AD-MSCs)。然而,基于细胞的疗法有其自身的局限性,特别是体现在该领域的专业技术和应用规则方面。有人提出使用AD-MSCs作为对抗COVID-19的武器进行生物治疗,因为它们具有免疫调节特性,能够对抗该疾病特有的细胞因子风暴,且其实用效率能切实帮助在全球范围内实现大规模治疗,可能会带来改变局面的效果。